Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 January, 2022 10:21 IST
Cadila Healthcare gets final approval from USFDA for Decitabine Injection
Source: IRIS | 22 Nov, 2021, 04.54PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Zydus Cadila has received final approval from the USFDA to market Decitabine for Injection in the strength of 50 mg/vial Single-Dose Vial (USRLD: Dacogen). Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer. The drug will be manufactured at the group’s injectables manufacturing facility at Zydus Hospira.

The group now has 326 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 7.45, or 1.61%, to trade  at  Rs 456.55.  The total volume of shares traded  was  169,895 at  the BSE (3.30 p.m, Monday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
VA Tech Wabag secures order worth USD 100 mn in Dubai - 17-Jan-2022 19:43
Glenmark Pharmaceuticals arm gets tentative approval for Regadenoson Injection - 17-Jan-2022 19:16
HDFC Bank Q3FY22 Review-Credit growth improved; Restructured assets at 1.37% vs 1.5% - 17-Jan-2022 17:25
HCL Technologies Q3FY22 Review- Margins to improve gradually - 17-Jan-2022 17:15
HDFC Bank: Earnings in line; Balance Sheet strengthens further - 17-Jan-2022 16:52
Renaissance Global partners with National Football League - 17-Jan-2022 11:26
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer